Annexon (NASDAQ:ANNX) Shares Gap Up After Analyst Upgrade

Posted by Francis Steltz on Jul 15th, 2026

Annexon, Inc. (NASDAQ:ANNX – Get Free Report) gapped up prior to trading on Wednesday after Needham & Company LLC raised their price target on the stock from $11.00 to $25.00. The stock had previously closed at $5.55, but opened at $5.87. Needham & Company LLC currently has a buy rating on the stock. Annexon shares last traded at $5.5770, with a volume of 265,260 shares trading hands.

Several other equities research analysts have also issued reports on the stock. The Goldman Sachs Group started coverage on shares of Annexon in a report on Tuesday, May 12th. They issued a “neutral” rating and a $7.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Monday. Wall Street Zen downgraded Annexon from a “hold” rating to a “sell” rating in a report on Sunday. Chardan Capital reiterated a “buy” rating and issued a $16.00 price objective on shares of Annexon in a research note on Friday, March 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Annexon in a report on Monday, April 20th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Annexon currently has an average rating of “Moderate Buy” and a consensus price target of $17.80.

Read Our Latest Research Report on ANNX

Insider Transactions at Annexon

In related news, Director William H. Carson purchased 8,000 shares of Annexon stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $5.78 per share, for a total transaction of $46,240.00. Following the transaction, the director directly owned 78,405 shares in the company, valued at approximately $453,180.90. This represents a 11.36% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Muneer A. Satter acquired 613,497 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were bought at an average cost of $5.41 per share, for a total transaction of $3,319,018.77. Following the acquisition, the director owned 10,342,134 shares in the company, valued at approximately $55,950,944.94. The trade was a 6.31% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 10.31% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. CIBC Bancorp USA Inc. acquired a new position in Annexon during the 3rd quarter worth $31,000. Engineers Gate Manager LP acquired a new stake in shares of Annexon in the 2nd quarter valued at $32,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Annexon by 65.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock valued at $35,000 after buying an additional 2,785 shares during the period. Landscape Capital Management L.L.C. bought a new stake in shares of Annexon during the fourth quarter worth $50,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of Annexon during the fourth quarter worth $52,000.

Annexon Price Performance

The firm has a 50 day moving average price of $5.35 and a 200-day moving average price of $5.56. The firm has a market cap of $910.62 million, a price-to-earnings ratio of -4.56 and a beta of 1.16.

Annexon (NASDAQ:ANNX – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.07. On average, sell-side analysts expect that Annexon, Inc. will post -0.92 EPS for the current fiscal year.

Annexon Company Profile

(Get Free Report)

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.